Eli Lilly spending $20B buying up companies — buy the expansion story
Eli Lilly has already announced over $20 billion worth of acquisitions in 2026, a record for the company, as it looks to grow beyond its massively successful weight-loss and diabetes drugs.
Idea
Eli Lilly is spending record amounts — over $20 billion so far in 2026 — to buy up other companies and expand beyond its blockbuster obesity drugs. That kind of aggressive shopping spree tells you management sees major growth opportunities ahead and is confident enough to put real money behind it. When a drugmaker of Lilly's size goes on a buying binge, investors usually reward the stock as new drugs and revenue streams get added to the pipeline. The risk is that acquisitions don't pan out or come with hefty integration costs, but the market has been cheering the strategy so far.